The More We Know: Evolving our understanding of PrEP for cisgender women
Science and real-world experience continue to demand a re-assessment of our collective understanding of the safety and effectiveness of PrEP options for women, including oral, vaginal ring, and injectable options.
For instance, a new paper in the Journal of the American Medical Association by Dr. Jeanne Marrazzo (HIV Pre-Exposure Prophylaxis with Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women) challenges the notion, baked into policies, programs and “conventional wisdom”, that cisgender women need to be “super-adherers” to achieve protection utilizing oral PrEP.
In this webinar, we discussed this important paper and more.
More from The Choice Agenda: avac.org/choice-agenda
![(EN)[Take care of me!] Episode 60](https://images.mixrolikus.cc/video/Nptbm-XfDyU)
